One of the most meaningful parts of the Bleeding Disorders Conference was the chance for people to gather in spaces that reflected their identities and experiences. This year, NBDF hosted a series of intersectional sessions and networking hours that…
Breakthrough sessions, hands-on workshops, and time together in community—Friday had it all. The day was full of learning, laughter, and moments that brought people closer.Browse our photo highlights to catch a glimpse of the day.
The last day of the 77th Annual Bleeding Disorders Conference brought inspiration at every turn—from sessions on data-driven research to stories from everyday heroes and celebrating leaders who make a difference. But the night was all about…
Research, Evidence-based Practice, and QI: A Roadmap for Multidisciplinary TeamsHealthcare providers face a sobering reality: 400,000 unintended patient deaths occur annually, with adverse events affecting one in four hospital admissions. Yet these…
The purpose of this project is to request support for the development of a computer-based training (CBT) module designed to teach the care and treatment of patients with bleeding disorders to nursing staff in a large, multi-campus pediatric…
Gene therapy was once hailed as the transformative breakthrough for hemophilia—the long-awaited cure that would change everything. But reality has been more nuanced, and many people in the community have been hesitant to embrace it. Some…
Join Dr. Young, speaking on behalf of HEMA Biologics, for an informative conversation about a treatment option for hemophilia A or B with inhibitors. This session will share helpful insights to help you better understand your options and feel more…
The Bleeding Disorders Research Collaborative (BDRC) aims to advance an accessible standard of care and quality of life for all people living with inheritable bleeding disorders. This goal will be achieved through collaborative and meaningful…
Federal: 2025 Bleeding Disorders Conference NBDF wrapped up another successful Bleeding Disorders Conference. The policy team was busy with sessions on blood and product safety, access to insurance, and…
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for VONVENDI®, which expands its indication to include prophylaxis use to reduce the frequency of bleeding episodes in adults with von Willebrand…